Featured Research

from universities, journals, and other organizations

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

Date:
November 9, 2011
Source:
Cardiovascular Research Foundation
Summary:
The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain types of patients, including smokers and those who are younger, are at higher risk, according to results of the DESERT registry.

The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain types of patients, including smokers and those who are younger, are at higher risk, according to results of the DESERT registry. Results of the trial were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Stent thrombosis, a condition in which blood clots form following the implantation of a stent, frequently presents as an acute event triggering myocardial infarction (MI, heart attack) or death. As single center studies are limited in their evaluation of ST, there is an existing need to understand the factors predicting ST and define those patients are that are at highest risk.

DESERT (Drug Eluting Stent Event Registry of Thrombosis), in which 922 patients from 20 sites from the United States, Canada and Switzerland have been enrolled in this multi-center, observational, case-control study of definite, late or very late ST in patients with drug-eluting stents (DES). DESERT is the largest case-control registry of late and very late definite stent thrombosis.

In the registry, the majority of late ST occurred after one year (~75%) and continued for up to 7.3 years. The clinical presentation of late ST was mainly myocardial infarction (66.9% STEMI; 22% NSTEMI). Nearly 30% of the patients with late stent thrombosis were on dual antiplatelet therapy (DAPT) at the time of the event.

"Patients who had first generation drug-eluting stents continue to be at risk for late stent thrombosis up to seven years," said lead investigator, Ron Waksman, MD. Dr. Waksman is Associate Director, Division of Cardiology at Washington Hospital Center (WHC) and Director of Experimental Angioplasty and Emerging Technologies at the Cardiovascular Research Institute (CRI) at WHC.

"Younger patients, smokers, African Americans, patients with multi-vessel disease, STEMI or saphenous vein grafts (SVG) should be reevaluated for drug-eluting stents or for a strong and longer term regimen of dual antiplatelet therapy," Dr. Waksman said.

The DESERT trial was investigation driven study is funded in part by Medtronic Vascular and by the investigators of the study. Dr. Waksman serves on the advisory board of several of the DES manufacturers tested in the study.


Story Source:

The above story is based on materials provided by Cardiovascular Research Foundation. Note: Materials may be edited for content and length.


Cite This Page:

Cardiovascular Research Foundation. "Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified." ScienceDaily. ScienceDaily, 9 November 2011. <www.sciencedaily.com/releases/2011/11/111109161343.htm>.
Cardiovascular Research Foundation. (2011, November 9). Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2011/11/111109161343.htm
Cardiovascular Research Foundation. "Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified." ScienceDaily. www.sciencedaily.com/releases/2011/11/111109161343.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins